Mauna Kea Technologies has secured CE Mark for the use of its multidisciplinary confocal laser endomicroscopy platform, Cellvizio, in minimally invasive laparoscopic surgical indications.

The European Union regulatory approval allows the use of Cellvizio to provide imaging support in an array of oncologic surgical procedures, many of which have already been investigated successfully in several clinical studies across Europe.

France’s University of Strasbourg IRCAD-EITS Dr Silvana Perretta said: "Cellvizio is able to provide important digital information in real-time, while overcoming the physical barrier of the OR.

"The ability to bring this new level of knowledge and precision into the surgical field is a significant advantage as the global focus on evidenced-based medicine continues to expand."

Mauna Kea Technologies founder Sacha Loiseau said: "While we view this achievement as an important regulatory milestone for the company, it is also the next step in our ongoing effort to position this technology to transform how surgery is performed in the years ahead.

"Cellvizio is an endomicroscopy system designed to generate optical biopsies, providing physicians with microscopic images of tissue instantaneously and in a minimally-invasive manner."

"Based on a rapidly growing body of clinical evidence, Cellvizio is the ideal technology for integration into many surgical and interventional image-guided platforms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Based on versatility and ease-of-use, we feel confident that adoption and use of this landmark technology will continue to expand rapidly in the EU and around the world."

Cellvizio is an endomicroscopy system designed to generate optical biopsies, providing physicians with microscopic images of tissue instantaneously and in a minimally-invasive manner.

Access to real-time visualisation of tissue is likely to provide a range of benefits to surgeons and patients such as improved frozen section sampling, more accurate tumour margin detection and improved surgical planning.

The system is compatible and synergistic with macroscopic optical fluorescent imaging systems used in a broad spectrum of surgical applications.

In the current setting, the Celioflex Cellvizio probe can be delivered laparoscopically through a trocar and manipulated in the surgical field with standard laparoscopic hand-held instruments.

According to the company, usage of the Cellvizio probe with robotic instruments will be accessible in the future.